Zonisamide

K K Jain MD (Dr. Jain is a consultant in neurology and has no relevant financial relationships to disclose.)
Originally released May 16, 2000; last updated April 7, 2016; expires April 7, 2019

Historical note and terminology

Zonisamide is chemically classified as a sulfonamide and is unrelated to other antiepileptic drugs.

Image: Zonisamide (chemical structure)
Originally developed in Japan for the treatment of epilepsy, it was later approved in 1989, and has since been licensed in many countries. It was under investigation for cerebral ischemia, but no development has been reported for this indication since 1994. Zonisamide was approved by the Food and Drug Administration in 2000 for marketing as an add-on adult focal epilepsy treatment. It is now approved in Europe as monotherapy for the treatment of partial seizures in adults affected by newly diagnosed epilepsy.

The content you are trying to view is available only to logged in, current MedLink Neurology subscribers.

If you are a subscriber, please log in.

If you are a former subscriber or have registered before, please log in first and then click select a Service Plan or contact Subscriber Services. Site license users, click the Site License Acces link on the Homepage at an authorized computer.

If you have never registered before, click Learn More about MedLink Neurology  or view available Service Plans.